Aarti Pharmalabs Ltd (AARTIPHARM) — Sustainability Report | 29 August 2026
Aarti Pharmalabs Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26 to BSE and NSE on August 29, 2026, as mandated under SEBI Regulation 34(2)(f). The report details ESG disclosures across operations, including carbon footprint, water and waste management, employee welfare, governance, and stakeholder engagement. It highlights a Type 2 Moderate assurance on sustainability indicators, proactive CSR initiatives in aspirational districts, and compliance with environmental and human rights standards. The company emphasizes sustainable sourcing, renewable energy adoption, and zero liquid discharge. Governance includes Board-level oversight via the Risk Management Committee. No material changes from the previous period were disclosed, and no forward guidance was provided. The filing underscores transparency and commitment to responsible business practices.
About Aarti Pharmalabs Ltd (AARTIPHARM)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when AARTIPHARM files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track AARTIPHARM — Free💡 Ask AI about this filing
📊 More AARTIPHARM filings
- 🔴 Corporate Action — 17 August 2026 Aarti Pharmalabs announced a final dividend of ₹2 per share (40% yield) for FY 2025-26, with a recor...
- Announcement — 17 August 2026 No summary available
- Announcement — 10 August 2026 Aarti Pharmalabs Limited announced that the audio recording of its earnings conference call for Q1 F...
- 🔴 Financial Results — 10 August 2026 Aarti Pharmalabs Limited reported standalone revenue of **₹5,346 crores** for Q1 FY27, up **42.4% Yo...
- 🟡 Board Meeting — 7 August 2026 Aarti Pharmalabs announced its August 7, 2026 board meeting outcome, approving unaudited standalone ...
🔥 Also filed on 29 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AARTIPHARM files new disclosures
Track AARTIPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AARTIPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd